Brief: Antengene And UCB Enter Global License Agreement For ATG-201, A CD19/CD3 Bispecific T-Cell Engager For Autoimmune Diseases
03/03/2026 22:03
March 3 (Reuters) - Antengene Corp Ltd 6996.HK: ANTENGENE AND UCB ENTER GLOBAL LICENSE AGREEMENT FOR ATG-201, A CD19/CD3 BISPECIFIC T-CELL ENGAGER FOR AUTOIMMUNE DISEASES ANTENGENE CORP - TO RECEIVE $80 MILLION UPFRONT, ELIGIBLE FOR OVER $1.1 BILLION IN MILESTONES AND ROYALTIES Source text: ID:nPrev8Ww3a Further company coverage: 6996.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on UCB SA
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: UCB Announces Data Showing Positive Impact Of Kygevvi In Tk2d Patients
Brief: UCB Completes $2.2 Billion Acquisition Of Candid Therapeutics
Europe Research Roundup: Banca Generali, Ferrari, Prysmian
Barclays downgrades UCB after rally, sees limited upside